Micrornas as therapeutics and biomarkers for epilepsy

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of specific microRNAs (miRNAs) as therapeutic agents, diagnostic biomarkers, and prognostic tools for epilepsy. The invention includes pharmaceutical compositions, vaccines, and diagnostic kits that target the dysregulation of miRNAs associated with epilepsy. These approaches can either restore normal miRNA levels or counteract their abnormal expression, which is implicated in the development and progression of epileptic conditions. The miRNAs can also be used as biomarkers to detect, monitor, and predict epilepsy or a predisposition to develop epilepsy.

Use CasesContent extracted from patent full text and abstract with AI.

• Developing new drugs or gene therapies that modulate specific miRNAs to treat or prevent epilepsy.
• Creating diagnostic tests (such as PCR or microarrays) that detect miRNA levels in bodily fluids (e.g., blood or cerebrospinal fluid) for early epilepsy diagnosis.
• Monitoring the effectiveness of epilepsy treatments by measuring changes in miRNA expression over time.
• Developing vaccines that use nucleic acids or antagonists of miRNAs to prevent the onset or recurrence of epilepsy.
• Stratifying patients by their miRNA biomarker profile to personalize epilepsy therapy or identify high-risk individuals.
• Screening for new compounds that can modulate the relevant miRNAs as part of epilepsy drug discovery.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new modality for epilepsy therapy, targeting the molecular mechanisms of disease rather than just symptoms.
• Allows for earlier and more accurate diagnosis and prognosis of epilepsy through biomarker detection.
• Improves the ability to monitor disease progression and response to treatment objectively.
• Enables personalized medicine approaches, tailoring therapy to the individual's molecular profile.
• Potentially reduces side effects by offering targeted therapy compared to current anti-epileptic drugs.
• Supports the discovery of new drug candidates targeting miRNA pathways relevant to epilepsy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a pharmaceutical composition for use in the treatment or prevention of epilepsy, comprising a means for alleviating or reversing the effect of a dysregulation of a miRNA molecule. The invention further relates to a vaccine for use in the treatment or prevention of epilepsy, to a biomarker or group of biomarkers associated with epilepsy, a composition for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or a predisposition for epilepsy, a method or assay for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or a predisposition for epilepsy. Also envisaged is a method for monitoring epilepsy therapy, a method of identifying an individual eligible for an epilepsy therapy, a corresponding diagnostic kit and the use of a biomarker or a group of biomarkers for diagnosing, detecting, graduating, monitoring or prognosticating epilepsy or for identifying pharmaceutically active agents useful in the treatment or prevention of epilepsy.